Genmin Lu, Joyce Lin, M. Bronson, M. Crowther, P. Conley, J. Curnutte
{"title":"独立于组织因子途径抑制剂的非组织因子启动凝血酶生成评估Andexanet Alfa对阿哌沙班和利伐沙班抗凝逆转ANNEXA-A和ANNEXA-R","authors":"Genmin Lu, Joyce Lin, M. Bronson, M. Crowther, P. Conley, J. Curnutte","doi":"10.33590/emjcardiol/10312045","DOIUrl":null,"url":null,"abstract":"Andexanet alfa is a modified factor Xa (FXa) drug designed to bind and sequester FXa inhibitors and thus reverse anticoagulation. The oral presentation reviewed in this article, presented by Dr Genmin Lu at the European Society of Cardiology (ESC) Congress 2018, provides new insights into the effect of the interaction between andexanet alfa and tissue factor (TF) pathway inhibitors on the restoration of thrombin generation (TG) in the TF (extrinsic) and non-TF (intrinsic) coagulation pathways.","PeriodicalId":284912,"journal":{"name":"EMJ Cardiology","volume":"28 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reversal of Apixaban and Rivaroxaban Anticoagulation by Andexanet Alfa in ANNEXA-A and ANNEXA-R as Assessed by Non-Tissue Factor-Initiated Thrombin Generation Independent of Tissue Factor Pathway Inhibitor\",\"authors\":\"Genmin Lu, Joyce Lin, M. Bronson, M. Crowther, P. Conley, J. Curnutte\",\"doi\":\"10.33590/emjcardiol/10312045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Andexanet alfa is a modified factor Xa (FXa) drug designed to bind and sequester FXa inhibitors and thus reverse anticoagulation. The oral presentation reviewed in this article, presented by Dr Genmin Lu at the European Society of Cardiology (ESC) Congress 2018, provides new insights into the effect of the interaction between andexanet alfa and tissue factor (TF) pathway inhibitors on the restoration of thrombin generation (TG) in the TF (extrinsic) and non-TF (intrinsic) coagulation pathways.\",\"PeriodicalId\":284912,\"journal\":{\"name\":\"EMJ Cardiology\",\"volume\":\"28 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMJ Cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33590/emjcardiol/10312045\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMJ Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33590/emjcardiol/10312045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Reversal of Apixaban and Rivaroxaban Anticoagulation by Andexanet Alfa in ANNEXA-A and ANNEXA-R as Assessed by Non-Tissue Factor-Initiated Thrombin Generation Independent of Tissue Factor Pathway Inhibitor
Andexanet alfa is a modified factor Xa (FXa) drug designed to bind and sequester FXa inhibitors and thus reverse anticoagulation. The oral presentation reviewed in this article, presented by Dr Genmin Lu at the European Society of Cardiology (ESC) Congress 2018, provides new insights into the effect of the interaction between andexanet alfa and tissue factor (TF) pathway inhibitors on the restoration of thrombin generation (TG) in the TF (extrinsic) and non-TF (intrinsic) coagulation pathways.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
